ICONIC THERAPEUTICS

iconic-therapeutics-logo

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. It is a biopharmaceutical company that has an exclusive license on issued Yale University patents for a novel recombinant protein called hI-con1. hI-con1 binds tissue factor (TF), triggering natural killer cells to selectively destroy pathologic neovascular blood vessels. Such cells include choroidal neovascularization (CNV) associated with wet age-related macular deg... eneration (wet AMD) and TF-expressing cancer cells and tumor-associated pathologic blood vessels (PBV). In addition to this cell-mediated cytotoxicity, hI-con1 may also interrupt the positive feedback loop between tissue factor and vascular endothelial growth factor (VEGF), thereby reducing VEGF levels. Phase 1 studies with hl-con1 are complete and no dose limited toxicities were observed. Evidence of dose-related biologic activity was observed.

#SimilarOrganizations #People #Financial #Website #More

ICONIC THERAPEUTICS

Social Links:

Industry:
Biopharma Biotechnology Therapeutics

Founded:
2002-01-01

Address:
South San Francisco, California, United States

Country:
United States

Website Url:
http://www.iconictherapeutics.com

Total Employee:
11+

Status:
Active

Contact:
(650) 437-1000

Email Addresses:
[email protected]

Total Funding:
82.85 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics Global Site Tag Nginx Euro


Similar Organizations

rainier-therapeutics-logo

Rainier Therapeutics

Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.


Current Advisors List

johan-kรถrdel_image

Johan Kรถrdel Member of the Board of Directors @ Iconic Therapeutics
Board_member

bruce-robertson_image

Bruce Robertson Board of Directors @ Iconic Therapeutics
Board_member

todd-foley_image

Todd Foley Board of Directors @ Iconic Therapeutics
Board_member

not_available_image

Jonathan Soderstrom Board of Directors @ Iconic Therapeutics
Board_member

Current Employees Featured

not_available_image

Patrick W. Trown
Patrick W. Trown Chief Scientist @ Iconic Therapeutics
Chief Scientist

george-g-montgomery_image

George G. Montgomery
George G. Montgomery Senior Vice President, Financial Strategy @ Iconic Therapeutics
Senior Vice President, Financial Strategy
2015-04-01

gabriela-burian_image

Gabriela Burian
Gabriela Burian Chief Medical Officer @ Iconic Therapeutics
Chief Medical Officer
2014-08-01

william-greene_image

William Greene
William Greene Chariman and CEO @ Iconic Therapeutics
Chariman and CEO
2014-04-01

Founder


kirk-dornbush_image

Kirk Dornbush

not_available_image

Michael Sherman

Investors List

hbm-partners_image

HBM Partners

HBM Partners investment in Venture Round - Iconic Therapeutics

janssen-labs_image

JLABS

JLABS investment in Venture Round - Iconic Therapeutics

cormorant-asset-management_image

Cormorant Asset Management

Cormorant Asset Management investment in Venture Round - Iconic Therapeutics

atdc_image

ATDC

ATDC investment in Venture Round - Iconic Therapeutics

mpm-capital_image

MPM Capital

MPM Capital investment in Venture Round - Iconic Therapeutics

lundbeckfond-ventures_image

Lundbeckfonden Ventures

Lundbeckfonden Ventures investment in Venture Round - Iconic Therapeutics

osage-university-partners_image

OUP (Osage University Partners)

OUP (Osage University Partners) investment in Venture Round - Iconic Therapeutics

elm-street-ventures_image

Elm Street Ventures

Elm Street Ventures investment in Venture Round - Iconic Therapeutics

hbm-healthcare-investments-ag_image

HBM Healthcare Investments AG

HBM Healthcare Investments AG investment in Venture Round - Iconic Therapeutics

diem-bioventures_image

Diem Bioventures

Diem Bioventures investment in Venture Round - Iconic Therapeutics

Official Site Inspections

http://www.iconictherapeutics.com

  • Host name: staticip2.multiscreensite.com
  • IP address: 100.24.208.97
  • Location: Ashburn United States
  • Latitude: 39.0481
  • Longitude: -77.4728
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20149

Loading ...

More informations about "Iconic Therapeutics"

Iconic Therapeutics - Crunchbase Company Profile

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. See details»

Iconic Therapeutics - 2025 Company Profile & Team - Tracxn

Jun 30, 2025 Iconic Therapeutics - Immunoconjugate proteins that trigger the immune system to destroy invader cells to treat AMD and ocular melanoma.. Acquired by Endpoint Health. โ€ฆ See details»

Iconic Therapeutics 2025 Company Profile: Valuation, โ€ฆ

Information on acquisition, funding, cap tables, investors, and executives for Iconic Therapeutics. Use the PitchBook Platform to explore the full profile. See details»

Iconic Therapeutics - Org Chart, Teams, Culture & Jobs | The Org

View Iconic Therapeutics' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. See details»

Iconic Therapeutics - Craft

Iconic Therapeutics has 5 employees across 2 locations and $82.5 m in total funding,. See insights on Iconic Therapeutics including office locations, competitors, revenue, financials, โ€ฆ See details»

Iconic Therapeutics, Inc. Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Iconic Therapeutics, Inc. of South San Francisco, CA. Get the latest business insights from Dun & โ€ฆ See details»

Overview, News & Similar companies - ZoomInfo.com

Jan 5, 2022 View Iconic Therapeutics (www.iconictherapeutics.com) location in California, United States , revenue, industry and description. Find related and similar companies as well โ€ฆ See details»

Iconic Therapeutics, Inc. | MedPath

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) Phase 2 Terminated Conditions Choroidal โ€ฆ See details»

Iconic Therapeutics Company Profile | Management and

Iconic Therapeutics Profile and History Iconic Therapeutics, Inc. is a venture-backed biopharmaceutical company dedicated to translating an understanding of the role of Tissue โ€ฆ See details»

Iconic Therapeutics Company Profile -Sales, Contacts, Competitors ...

This organization primarily operates in the Pharmaceutical Preparations business / industry within the Chemicals and Allied Products sector. This organization has been operating for โ€ฆ See details»

Iconic Therapeutics company information, funding & investors

Iconic Therapeutics, clinical stage biopharmaceutical company dedicated to translating scientific insight into breakthrough medicines. Here you'll find information about their funding, investors โ€ฆ See details»

Iconic Therapeutics, Inc. Overview | SignalHire Company Profile

Iconic Therapeutics, Inc. is a private company that has been in the industry for 21 years. The company currently specializes in the Biotechnology, Biotechnology areas. The position of the โ€ฆ See details»

Iconic Therapeutics | Elm Street Ventures - A Yale Focused Venture โ€ฆ

Elm Street Ventures partner Mike Sherman (now retired) was a co-founder of the company, which raised its first capital in 2003, and served as the CEO and Chairman. Iconic raised a โ€ฆ See details»

Iconic Therapeutics - Portfolio Company Profile, Executives and โ€ฆ

See Iconic Therapeutics's complete profile, including its private equity owner and the number of its executive contacts in our database. Iconic Therapeutics is a clinical stage โ€ฆ See details»

Iconic Therapeutics - VentureRadar

"Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and โ€ฆ See details»

Iconic Therapeutics - Profiles & Contacts - Crunchbase

Iconic Therapeutics develops and commercializes immunoconjugate proteins that trigger the immune system to destroy invader cells. See details»

Iconic Therapeutics, Inc. (Iconic Therapeutics, Inc.) - ่ฏ็‰ฉ็ฎก็บฟ_ไธ“ โ€ฆ

Jun 15, 2025 The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in โ€ฆ See details»

ICONIC THERAPEUTICS CLOSES SERIES C FINANCING WITH NEW โ€ฆ

Matthias Fehr, Ph.D., CFA, Investment Advisor at HBM Partners, Ltd., said, We believe that Iconic has the potential to be the first company to successfully target Tissue Factor. This historically โ€ฆ See details»

Iconic Therapeutics - VentureRadar

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and โ€ฆ See details»

Meet the biotech-company founders driven by their childโ€™s

1 day ago For some parents, finding a cure for their childโ€™s illness is the ultimate motivation to start a company. See details»

linkstock.net © 2022. All rights reserved